Literature DB >> 24335299

Ablation of nectin4 binding compromises CD46 usage by a hybrid vesicular stomatitis virus/measles virus.

Yu-Ping Liu1, Samuel P Russell, Camilo Ayala-Breton, Stephen J Russell, Kah-Whye Peng.   

Abstract

Measles virus (MV) immunosuppression is due to infection of SLAM-positive immune cells, whereas respiratory shedding and virus transmission are due to infection of nectin4-positive airway epithelial cells. The vaccine lineage MV strain Edmonston (MV-Edm) acquired an additional tropism for CD46 which is the basis of its oncolytic specificity. VSVFH is a vesicular stomatitis virus (VSV) encoding the MV-Edm F and H entry proteins in place of G. The virus spreads faster than MV-Edm and is highly fusogenic and a potent oncolytic. To determine whether ablating nectin4 tropism from VSVFH might prevent shedding, increasing its safety profile as an oncolytic, or might have any effect on CD46 binding, we generated VSVFH viruses with H mutations that disrupt attachment to SLAM and/or nectin4. Disruption of nectin4 binding reduced release of VSVFH from the basolateral side of differentiated airway epithelia composed of Calu-3 cells. However, because nectin4 and CD46 have substantially overlapping receptor binding surfaces on H, disruption of nectin4 binding compromised CD46 binding and greatly diminished the oncolytic potency of these viruses on human cancer cells. Thus, our results support continued preclinical development of VSVFH without ablation of nectin4 binding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24335299      PMCID: PMC3911550          DOI: 10.1128/JVI.02628-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  In vitro study of the pulmonary translocation of nanoparticles: a preliminary study.

Authors:  J Geys; L Coenegrachts; J Vercammen; Y Engelborghs; A Nemmar; B Nemery; P H M Hoet
Journal:  Toxicol Lett       Date:  2005-08-30       Impact factor: 4.372

2.  Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.

Authors:  Hooi Tin Ong; Michael M Timm; Philip R Greipp; Thomas E Witzig; Angela Dispenzieri; Stephen J Russell; Kah-Whye Peng
Journal:  Exp Hematol       Date:  2006-06       Impact factor: 3.084

3.  Structure of the measles virus hemagglutinin bound to the CD46 receptor.

Authors:  César Santiago; María L Celma; Thilo Stehle; José M Casasnovas
Journal:  Nat Struct Mol Biol       Date:  2009-12-13       Impact factor: 15.369

Review 4.  Use of attenuated paramyxoviruses for cancer therapy.

Authors:  Patrycja J Lech; Stephen J Russell
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

5.  A single amino acid change in the hemagglutinin protein of measles virus determines its ability to bind CD46 and reveals another receptor on marmoset B cells.

Authors:  E C Hsu; F Sarangi; C Iorio; M S Sidhu; S A Udem; D L Dillehay; W Xu; P A Rota; W J Bellini; C D Richardson
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed.

Authors:  Vincent H J Leonard; Patrick L Sinn; Gregory Hodge; Tanner Miest; Patricia Devaux; Numan Oezguen; Werner Braun; Paul B McCray; Michael B McChesney; Roberto Cattaneo
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

7.  Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys.

Authors:  Vincent H J Leonard; Gregory Hodge; Jorge Reyes-Del Valle; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

8.  Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity.

Authors:  Ralf Buettner; Mei Huang; Tanya Gritsko; Jim Karras; Steve Enkemann; Tania Mesa; Sangkil Nam; Hua Yu; Richard Jove
Journal:  Mol Cancer Res       Date:  2007-08       Impact factor: 5.852

9.  Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.

Authors:  Nathan Jenks; Rae Myers; Suzanne M Greiner; Jill Thompson; Emily K Mader; Andrew Greenslade; Guy E Griesmann; Mark J Federspiel; Jorge Rakela; Mitesh J Borad; Richard G Vile; Glen N Barber; Thomas R Meier; Michael C Blanco; Stephanie K Carlson; Stephen J Russell; Kah-Whye Peng
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

10.  Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Authors:  Evanthia Galanis; Lynn C Hartmann; William A Cliby; Harry J Long; Prema P Peethambaram; Brigitte A Barrette; Judith S Kaur; Paul J Haluska; Ileana Aderca; Paula J Zollman; Jeff A Sloan; Gary Keeney; Pamela J Atherton; Karl C Podratz; Sean C Dowdy; C Robert Stanhope; Timothy O Wilson; Mark J Federspiel; Kah-Whye Peng; Stephen J Russell
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

View more
  8 in total

1.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

Review 2.  Potential and clinical translation of oncolytic measles viruses.

Authors:  Steven Robinson; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2017-03       Impact factor: 4.388

3.  Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.

Authors:  Eugene S Bah; Rebecca A Nace; Kah Whye Peng; Miguel Ángel Muñoz-Alía; Stephen J Russell
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261

4.  Hemagglutinin-specific neutralization of subacute sclerosing panencephalitis viruses.

Authors:  Miguel Ángel Muñoz-Alía; Claude P Muller; Stephen J Russell
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

5.  MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.

Authors:  Miguel Ángel Muñoz-Alía; Rebecca A Nace; Alexander Tischer; Lianwen Zhang; Eugene S Bah; Matthew Auton; Stephen J Russell
Journal:  PLoS Pathog       Date:  2021-02-03       Impact factor: 6.823

6.  Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins.

Authors:  Miguel Ángel Muñoz-Alía; Rebecca A Nace; Lianwen Zhang; Stephen J Russell
Journal:  Cell Rep Med       Date:  2021-03-30

Review 7.  The tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses.

Authors:  Sebastien Delpeut; Ryan S Noyce; Christopher D Richardson
Journal:  Viruses       Date:  2014-06-02       Impact factor: 5.048

Review 8.  Viral Pathogenesis, Recombinant Vaccines, and Oncolytic Virotherapy: Applications of the Canine Distemper Virus Reverse Genetics System.

Authors:  Jianjun Zhao; Yanrong Ren; Jie Chen; Jiasan Zheng; Dongbo Sun
Journal:  Viruses       Date:  2020-03-20       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.